Shkreli claims rivals had access to Daraprim ingredient

Vyera Pharmaceuticals' exclusivity contracts for access to the active pharmaceutical ingredient in its parasite-fighting drug Daraprim did not foreclose generic competition, the company’s founder has argued.

Get unlimited access to all Global Competition Review content